GU CANCERS SYMPOSIUM 2024 ROUNDTABLE DISCUSSION: SC Nivolumab
OR
Chair
Dr. Nazanin Fallah-Rad
Panelists
Dr. Sebastien Hotte
Dr. Maria Jiang
This program has been made possible through unrestricted support from EMD Serono & Ipsen
Studies/trials discussed:
- SC Nivolumab Study
- Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.
